References
- US FDA. CDER Biomarker Qualification Program (2018). www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/BiomarkerQualificationProgram/ucm535922.htm#what-is
- Temple RJ . A regulatory authority's opinion about surrogate end points. In: Clinical Measurement in Drug Evaluation.NimmoWS, TuckerGT, ( Eds). Wiley, NY, USA (1995).
- US FDA. CDER Biomarker Qualification Program (2018). www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/BiomarkerQualificationProgram/ucm535882.htm
- US FDA. Guidance for Industry and FDA Staff: Qualification for Drug Development Tools (2014). www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597.pdf
- Amur S , LaVangeL, ZinehI, Buckman-GarnerS, WoodcockJ. Biomarker qualification: toward a multiple stakeholder framework for biomarker development, regulatory acceptance, and utilization. Clin. Pharmacol. Ther.98(1), 34–46 (2015).
- US FDA. Guidance for Industry: Bioanalytical Method Validation (2018). www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf
- Krishna R , HermanG, WagnerJA. Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for Type 2 diabetes. AAPS J.10(2), 401–409 (2008).
- Yu C , BashawED. Regulatory perspective of bioanalysis from a clinical pharmacology reviewer standpoint: do you see what I see?Bioanalysis6(4), 505–510 (2014).
- BEST glossary (2018). www.ncbi.nlm.nih.gov/books/NBK338448/